Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards - Jun 15, 2020

Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM), announced today the U.S. Food and Drug Administration (FDA) cleared its next-generation FreeStyle® Libre 2

Continuous Glucose Monitoring Sensors for Diabetes Management: A Review of Technologies and Applications

FreeStyle Libre 2 Continuous Glucose Monitor

Freestyle Libre 2 - Continuous Glucose Monitoring System

PDF) Landscape of Continuous Glucose Monitoring (CGM) and Integrated CGM: Accuracy Considerations

FreeStyle Libre 2 System (CGM)

Improving Equitable Access to Continuous Glucose Monitors for Alabama's Children with Type 1 Diabetes: A Quality Improvement Project

Abbott's FreeStyle® Libre 2 iCGM Cleared in U.S. for Adults and Children with Diabetes, Achieving Highest Level of Accuracy and Performance Standards

FreeStyle Libre 2 Continuous Glucose Monitor

ADA: Real-world data show lower A1c levels with Abbott's FreeStyle Libre CGM in Type 2 diabetes

Freestyle Libre 2 - Continuous Glucose Monitoring System

Freestyle Libre 2 CGM, Strategy and Strength

FreeStyle Libre Continuous Glucose Monitoring

Diabetes Technology Meeting 2020 - Trisha Shang, Jennifer Y. Zhang, B. Wayne Bequette, Jennifer K. Raymond, Gerard Coté, Jennifer L. Sherr, Jessica Castle, John Pickup, Yarmela Pavlovic, Juan Espinoza, Laurel H. Messer